BACKGROUND: Inflammatory breast cancer (IBC) is an aggressive disease. To date, no molecular feature reliably predicts either the response to chemotherapy (CT) or the survival. Using DNA microarrays, we searched for multigene predictors. PATIENTS AND METHODS: The World IBC Consortium generated whole-genome expression profiles of 137 IBC and 252 non-IBC (nIBC) samples. We searched for transcriptional profiles associated with pathological complete response (pCR) to neoadjuvant anthracycline-based CT and distant metastasis-free survival (DMFS) in respective subsets of 87 and 106 informative IBC samples. Correlations were investigated with predictive and prognostic gene expression signatures published in nIBC (nIBC-GES). Supervised analyses tested genes and activation signatures of 19 biological pathways and 234 transcription factors. RESULTS: Three of five tested prognostic nIBC-GES and the two tested predictive nIBC-GES discriminated between IBC with and without pCR, as well as two interferon activation signatures. We identified a 107-gene signature enriched for immunity-related genes that distinguished between responders and nonresponders in IBC. Its robustness was demonstrated by external validation in three independent sets including two IBC sets and one nIBC set, with independent significant predictive value in IBC and nIBC validation sets in multivariate analysis. We found no robust signature associated with DMFS in patients with IBC, and neither of the tested prognostic GES, nor the molecular subtypes were informative, whereas they were in our nIBC series (220 stage I-III informative samples). CONCLUSION: Despite the relatively small sample size, we show that response to neoadjuvant CT in IBC is, as in nIBC, associated with immunity-related processes, suggesting that similar mechanisms responsible for pCR exist. Analysis of a larger IBC series is warranted regarding the correlation of gene expression profiles and DMFS.
BACKGROUND:Inflammatory breast cancer (IBC) is an aggressive disease. To date, no molecular feature reliably predicts either the response to chemotherapy (CT) or the survival. Using DNA microarrays, we searched for multigene predictors. PATIENTS AND METHODS: The World IBC Consortium generated whole-genome expression profiles of 137 IBC and 252 non-IBC (nIBC) samples. We searched for transcriptional profiles associated with pathological complete response (pCR) to neoadjuvant anthracycline-based CT and distant metastasis-free survival (DMFS) in respective subsets of 87 and 106 informative IBC samples. Correlations were investigated with predictive and prognostic gene expression signatures published in nIBC (nIBC-GES). Supervised analyses tested genes and activation signatures of 19 biological pathways and 234 transcription factors. RESULTS: Three of five tested prognostic nIBC-GES and the two tested predictive nIBC-GES discriminated between IBC with and without pCR, as well as two interferon activation signatures. We identified a 107-gene signature enriched for immunity-related genes that distinguished between responders and nonresponders in IBC. Its robustness was demonstrated by external validation in three independent sets including two IBC sets and one nIBC set, with independent significant predictive value in IBC and nIBC validation sets in multivariate analysis. We found no robust signature associated with DMFS in patients with IBC, and neither of the tested prognostic GES, nor the molecular subtypes were informative, whereas they were in our nIBC series (220 stage I-III informative samples). CONCLUSION: Despite the relatively small sample size, we show that response to neoadjuvant CT in IBC is, as in nIBC, associated with immunity-related processes, suggesting that similar mechanisms responsible for pCR exist. Analysis of a larger IBC series is warranted regarding the correlation of gene expression profiles and DMFS.
Entities:
Keywords:
gene expression; inflammatory breast cancer; profiling; prognosis; response to chemotherapy
Authors: Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark Journal: N Engl J Med Date: 2004-12-10 Impact factor: 91.245
Authors: Steven Van Laere; Ilse Van der Auwera; Gert G Van den Eynden; Stephen B Fox; Fabrizio Bianchi; Adrian L Harris; Peter van Dam; Eric A Van Marck; Peter B Vermeulen; Luc Y Dirix Journal: Breast Cancer Res Treat Date: 2005-10 Impact factor: 4.872
Authors: Ivan Bièche; Florence Lerebours; Sengül Tozlu; Marc Espie; Michel Marty; Rosette Lidereau Journal: Clin Cancer Res Date: 2004-10-15 Impact factor: 12.531
Authors: B Chevallier; P Chollet; Y Merrouche; H Roche; P Fumoleau; P Kerbrat; J Y Genot; P Fargeot; J P Olivier; C Fizames Journal: J Clin Oncol Date: 1995-07 Impact factor: 44.544
Authors: Marc J van de Vijver; Yudong D He; Laura J van't Veer; Hongyue Dai; Augustinus A M Hart; Dorien W Voskuil; George J Schreiber; Johannes L Peterse; Chris Roberts; Matthew J Marton; Mark Parrish; Douwe Atsma; Anke Witteveen; Annuska Glas; Leonie Delahaye; Tony van der Velde; Harry Bartelink; Sjoerd Rodenhuis; Emiel T Rutgers; Stephen H Friend; René Bernards Journal: N Engl J Med Date: 2002-12-19 Impact factor: 91.245
Authors: Steven J Van Laere; Naoto T Ueno; Pascal Finetti; Peter Vermeulen; Anthony Lucci; Fredika M Robertson; Melike Marsan; Takayuki Iwamoto; Savitri Krishnamurthy; Hiroko Masuda; Peter van Dam; Wendy A Woodward; Patrice Viens; Massimo Cristofanilli; Daniel Birnbaum; Luc Dirix; James M Reuben; François Bertucci Journal: Clin Cancer Res Date: 2013-02-08 Impact factor: 12.531
Authors: Holly K Dressman; Christopher Hans; Andrea Bild; John A Olson; Eric Rosen; P Kelly Marcom; Vlayka B Liotcheva; Ellen L Jones; Zeljko Vujaskovic; Jeffrey Marks; Mark W Dewhirst; Mike West; Joseph R Nevins; Kimberly Blackwell Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531
Authors: Scott J Sauer; Michael Tarpley; Imran Shah; Akshay V Save; H Kim Lyerly; Steven R Patierno; Kevin P Williams; Gayathri R Devi Journal: Carcinogenesis Date: 2017-03-01 Impact factor: 4.944
Authors: Naoto T Ueno; Savitri Krishnamurthy; Jennifer A Wargo; Elizabeth A Mittendorf; Sangeetha M Reddy; Alexandre Reuben; Souptik Barua; Hong Jiang; Shaojun Zhang; Linghua Wang; Vancheswaran Gopalakrishnan; Courtney W Hudgens; Michael T Tetzlaff; James M Reuben; Takahiro Tsujikawa; Lisa M Coussens; Khalida Wani; Yan He; Lily Villareal; Anita Wood; Arvind Rao; Wendy A Woodward Journal: Cancer Immunol Res Date: 2019-05-01 Impact factor: 11.151
Authors: Angie M Torres-Adorno; Jangsoon Lee; Takahiro Kogawa; Peter Ordentlich; Debu Tripathy; Bora Lim; Naoto T Ueno Journal: Clin Cancer Res Date: 2017-05-02 Impact factor: 12.531
Authors: Jennifer L Allensworth; Myron K Evans; François Bertucci; Amy J Aldrich; Richard A Festa; Pascal Finetti; Naoto T Ueno; Rachid Safi; Donald P McDonnell; Dennis J Thiele; Steven Van Laere; Gayathri R Devi Journal: Mol Oncol Date: 2015-02-21 Impact factor: 6.603
Authors: François Bertucci; Laurys Boudin; Pascal Finetti; Christophe Van Berckelaer; Peter Van Dam; Luc Dirix; Patrice Viens; Anthony Gonçalves; Naoto T Ueno; Steven Van Laere; Daniel Birnbaum; Emilie Mamessier Journal: Oncoimmunology Date: 2021-05-23 Impact factor: 8.110